# EDGAR Filing Document

**Accession Number:** 0001784440
**File Stem:** 0001185185-25-001901
**Filing Date:** 2025-12
**Character Count:** 3229
**Document Hash:** 1750604c1a8270bebea73a318ae40481
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-25-001901.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001185185-25-001901

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioScience Health Innovations, Inc.
- **CENTRAL INDEX KEY:** 0001784440
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2722 S WEST TEMPLE
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84115
- **BUSINESS PHONE:** 801-949-0791

**MAIL ADDRESS:**
- **STREET 1:** 2722 S WEST TEMPLE
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nowtransit Inc
- **DATE OF NAME CHANGE:** 20190802

**BIOSCIENCE HEALTH INNOVATIONS INC.**

December 2, 2025

US Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **BioScience Health Innovations, Inc.** |
|  | **Offering Statement on Form 1-A** |
|  | **Filed November 25, 2025** |
|  | **File No. 024-12687** |

---

Dear Ladies and Gentlemen:

Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), BioScience Health Innovations Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") issue a qualification order for the above referenced Offering Statement on Form 1A, so that it may be qualified by 4:00 pm., Eastern Time on Thursday, December 4, 2025, or as soon thereafter as is practicable.

We understand that the Commission will not be reviewing the filing.

The Company is aware of its responsibilities under the Act, as they relate to this offering of securities. As requested, the Company further acknowledges that:

● Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;

● The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its responsibility for the adequacy and accuracy of the disclosures in the filing; and

● The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

If you have any questions, please contact our counsel, Jonathan Leinwand (954) 903-7856.

Thank you in advance for your assistance.

Very Truly Yours,

**BIOSCIENCE HEALTH INNOVATIONS INC.**

---

| | |
|:---|:---|
| By: | /s/ *Darren Lopez* |
|  | Darren Lopez, CEO/ <br> (Principal Executive Officer) |

---

2722 South West Temple

Salt Lake City, UT 84115